US equities |
NVDA $186.64 ▲+2.78% MU $690.00 ▲+5.12% AMD $449.04 ▲+11.04% SPCX $134.27 ▲+8.62% AAPL $342.37 ▼-0.52% SNDK $835.06 ▲+3.55% MSFT $530.61 ▼-0.99% TSLA $358.22 ▲+4.23%
FinancialContent

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

0.2235 +0.0097 (+4.54%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Acumen Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Unusual-Volume Stocks: Latest Session's Sharp Declines and Double-Digit Gains ↗
Via Chartmill
News headline image
Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors ↗
A single confirmatory Phase III trial design could streamline the path to regulatory approval if November data validates the oligomer-targeting approach. 
Via The Motley Fool
Topics Earnings
US Unusual Volume Stocks: ONEG, CENN, SLGB and INLF in Latest Scan ↗
Via Chartmill
Small-Cap Market Movers: Top Gainers and Losers on Nov. 2, 2026 ↗
Via Chartmill
Acumen Pharmaceuticals (NASDAQ:ABOS) Narrows Q3 Loss as ALTITUDE-AD Readout Looms ↗
Via Chartmill
Acumen Pharmaceuticals (NASDAQ:ABOS) Q1 2026 Loss Narrows as Phase 2 Alzheimer's Trial Readout Looms ↗
Via Chartmill
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
Postmarket Movers: After-Hours Gainers and Losers ↗
Via Chartmill
Most Active Stocks on Oct. 30, 2026: Intel, ChowChow Cloud and Acumen in Focus ↗
Via Chartmill
News headline image
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript ↗
Sabirnetug topline results expected November 2026 for early Alzheimer's disease trial. 
Via The Motley Fool
Topics Earnings
News headline image
Acumen Pharmaceuticals Q3 Earnings Call Highlights ↗
Acumen Pharmaceuticals (NASDAQ:ABOS) said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble... 
Via MarketBeat
Topics Earnings
News headline image
Acumen Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
A Preview Of Acumen Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Acumen Pharmaceuticals Q2 Earnings Call Highlights ↗
Acumen Pharmaceuticals (NASDAQ:ABOS) said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to... 
Via MarketBeat
Topics Earnings
News headline image
Acumen (ABOS) Q1 2026 Earnings Transcript ↗
Acumen (ABOS) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Acumen Pharmaceuticals Q1 Earnings Call Highlights ↗
Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader... 
Via MarketBeat
Topics Earnings
News headline image
Preview: Acumen Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Acumen Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
These stocks have an unusual volume in today's session ↗
Via Chartmill
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates ↗
Acumen Pharmaceuticals posts better-than-expected Q3 2025 results, advancing its Alzheimer's treatment pipeline with cash into 2027. 
Via Chartmill
Topics Earnings
News headline image
Preview: Acumen Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million. 
Via Benzinga
News headline image
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >